Immune Biosolutions Inc.
$13,442,000.00 CAD
- Program
- SIF Stream 1- R&D
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- April 29, 2020 – September 30, 2023
- Reference
- ic:033-2020-2021-Q4-513419
Published purpose
Immune Biosolutions inc. will develop a medical counter measure (MCM) and contribute to Canada's ability to secure an effective therapeutic in response to COVID-19.
In plain English AI-generated
Immune Biosolutions Inc. will develop a medical countermeasure to help secure an effective therapeutic response to COVID-19 in Canada.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.